Scarica l'app Stockscreener
5.37
10.20%
-0.61
Dopo l'orario di chiusura:
5.35
-0.02
-0.37%
Leonabio Inc Borsa (LONA) Ultime notizie
LeonaBio CEO Litton sells $27,687 in shares By Investing.com - Investing.com India
Renninger, LeonaBio CFO, sells $4.9k in LONA stock By Investing.com - Investing.com India
Renninger, LeonaBio CFO, sells $4.9k in LONA stock - Investing.com
Athira Pharma (LONA) 10K Form and SEC Filings 2026 $LONA - MarketBeat
Cantor Fitzgerald initiates Leona Bio stock with overweight rating By Investing.com - Investing.com Australia
LeonaBio initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald Initiates Coverage on LeonaBio With Overweight Rating - marketscreener.com
LONA Technical Analysis & Stock Price Forecast - Intellectia AI
LONA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LeonaBio, Inc. (prev. ATHA) (LONA) Stock Price Today | Live Chart & News - Traders Union
LeonaBio Shares Rise After Mizuho Securities Upgrade - marketscreener.com
LeonaBio (LONA) Receives Upgrade to Outperform by Mizuho | LONA Stock News - GuruFocus
Mizuho Securities Upgrades LeonaBio to Outperform From Neutral, Price Target is $4 - marketscreener.com
Mizuho upgrades LeonaBio stock rating on breast cancer drug potential By Investing.com - Investing.com India
Mizuho upgrades LeonaBio stock rating on breast cancer drug potential - Investing.com
Mizuho Securities Initiates LeonaBio(LONA.US) With Buy Rating, Announces Target Price $10 - 富途牛牛
LeonaBio (ATHA) proxy asks investors to back warrant share issuances and 2026 equity plan - stocktitan.net
LeonaBio appoints Mark Kubik as chief business officer By Investing.com - Investing.com Nigeria
Leonabio, Inc. Announces the Appointment of Mark F. Kubik as Chief Business Officer - marketscreener.com
LeonaBio (LONA) Names Mark Kubik as New Chief Business Officer - GuruFocus
LeonaBio appoints Mark Kubik as chief business officer - Investing.com
LeonaBio, Inc. Appoints Mark F. Kubik as Chief Business Officer to Drive Business Development Strategy - Quiver Quantitative
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer - marketscreener.com
Biopharma deal veteran to drive LeonaBio’s Phase 3 breast cancer drug - Stock Titan
Leonabio Inc files for offering of up to 58.5 million shares of common stock by the selling stockholders - marketscreener.com
Leonabio Inc Files For Offering Of Up To 58.5 Million Shares Of Common Stock By The Selling Stockholders - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA" - Investing News Network
LONA Stock Price and Chart — NASDAQ:LONA - TradingView
Athira Pharma (ATHA) Options to Be Delisted on January 12th - GuruFocus
LONA Stock Price, News & Analysis - Stock Titan
Athira Pharma Rebrands as LeonaBio, Refocusing on Oncology - TipRanks
Athira Pharma announces name change to LeonaBio - TipRanks
Athira Pharma roars into the new year with rebrand to LeonaBio - Fierce Pharma
Athira Pharma changes name, ticker symbol - MSN
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy - Investing.com Nigeria
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy By Investing.com - Investing.com South Africa
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” - Yahoo Finance
New breast cancer drug moves into late testing with $236M funding deal - Stock Titan
Athira Pharma (NASDAQ: ATHA) posts $6.6M Q3 loss; ATH-1105 study shows favorable safety, CNS penetration - Stock Titan
Athira Pharma announces reverse stock split - marketscreener.com
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 - GlobeNewswire
ATHA SEC FilingsAthira Pharma, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
ATHA Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Breakthrough ALS Drug ATH-1105 Achieves Key Safety Milestones, Targets Patient Trials Late 2025 - Stock Titan
Athira Pharma Slides As Insider Purchases Lose Another US$89k - simplywall.st
ATHA Stock Price, News & Analysis - stocktitan.net
Athira Pharma's ALS Drug Shows Promising Neuroprotective Effects in Key Preclinical Study - Stock Titan
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - marketscreener.com
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology - marketscreener.com
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference - Stock Titan
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND - marketscreener.com
Athira Pharma, Inc. Plans to Further Extend the Current OLEX for the Phase 2/3 LIFT-AD and Phase 2 ACT-AD Trials - marketscreener.com
Athira Pharma Provides 2023 Pipeline Outlook - marketscreener.com
Goldman Sachs Adjusts Price Target for Athira Pharma to $3 From $11, Maintains Neutral Rating - marketscreener.com
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates - marketscreener.com
Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth - simplywall.st
Alzheimer’s Disease Stock Cortexyme Craters on Trial Failure - Bloomberg.com
ATHA Stock Price, Forecast & Analysis | ATHIRA PHARMA INC (NASDAQ:ATHA) - ChartMill
ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):